La prévalence des effets indésirables de l’hormonothérapie dans le cancer du sein.

Abstract

Introduction: The recent evolution of therapeutic protocols for breast cancer, the frequent prescription of adjuvant hormone therapy and the recent diversification of available molecules have opened up a new field of study concerning the occurrence of adverse effects which have a drastic impact on patients' quality of life. Our aim is to assess the prevalence of adverse events related to antihormonal therapy in patients with hormone receptor-positive breast cancer at the Sétif CLCC. Method: our study is a retrospective cohort survey conducted over a period from January 1st,2023 to April 30th, 2023. It enrolled 55 patients with hormone-dependent breast cancer in the medical oncology center in the wilaya of Sétif (CLCC Sétif). Results: Among the patients treated in the medical oncology center of the Sétif, 55 were included in our study. The average age was 57 years. The breast cancer in question was hormone-dependent. Our study included patients of both menopausal and non-menopausal status. Virtually all patients complained of at least one adverse effect; 78.2% of women experienced hot flushes, 85.5% arthralgia, 83.6% anxiety, 40% weight gain and 20% gynecological problems. Conclusion: Hormone therapy for women with breast cancer in Sétif is a real problem for patients because of the prevalence and intensity of its adverse effects, which must be maintained to ensure better adherence to treatment and optimal quality of life